权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Formulation of a prophylactic vaccine against Pseudomonas aeruginosa

铜绿假单胞菌预防性疫苗的配制

基本信息

批准号：
10592374
负责人：
Aaron C Nagel
金额：
$ 30万
依托单位：
HAFION, LLC
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-03-16 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10592374
关键词：
Acute Adjuvant Adult Age Aging Agonist Animal Model Antibiotic Resistance Antigens Biochemistry Burn injury Catheterization Cell membrane Cells Cessation of life Chronic Clinical Critical Illness Dendritic Cells Development Diameter Dose Elderly Emulsions Formulation Goals Hospitalization Human IL17 gene Infection Injury Intubation Licensing Lipid A Lung Lung infections Marketing Microbial Biofilms Military Personnel Mission Modeling Morbidity - disease rate Mus Needles Nose Oils Oryctolagus cuniculus Outcome Pathogenesis Patient Care Patients Phase Pneumonia Population Populations at Risk Preventive vaccine Primary Infection Procedures Proteins Pseudomonas aeruginosa Pseudomonas aeruginosa infection Pseudomonas aeruginosa pneumonia Public Health Risk Factors Sales Serotyping Signal Transduction Small Business Innovation Research Grant Structure of germinal center of lymph node TLR4 gene Target Populations Technology Teenagers Toxic effect Toxin Type III Secretion System Pathway Vaccinated Vaccination Vaccines Virulent Water Work care costs combat injury cystic fibrosis infection cystic fibrosis patients efficacy evaluation enterotoxigenic Escherichia coli human disease human pathogen improved lymph nodes mortality mouse model multidrug-resistant Pseudomonas aeruginosa novel pneumonia model prevent protective efficacy response therapeutic vaccine vaccine development vaccine formulation vaccinology wound

项目摘要

SUMMARY Pseudomonas aeruginosa (Pa) is an important opportunistic human pathogen that causes severe infections in patients with burns, severe wounds, pneumonia, and critically ill patients who require intubation or catheterization. Clearing Pa is difficult due to antibiotic resistance. There are ~32,600 cases of multi-drug resistant (MDR) Pa in hospitalized patients annually with 2700 deaths and $757 million in patient care costs. Additionally, Pa is the major cause of pulmonary infections in cystic fibrosis (CF) patients with >70% of this population being chronically colonized by their teens. Military personnel are gravely impacted by the occurrence of MDR Pa in combat-related injuries. Equally important is the fact that the biggest risk factor for negative outcomes associated with infection by MDR Pa is advanced age. After age 60, there is a significant increase in morbidity and mortality resulting from MDR Pa infection. Thus, a broadly protective Pa vaccine has large market potential with up to three vaccinations providing complete protection to all humans. Hundreds of millions of vaccine doses would be given annually, approaching ~$5B in sales. While there are Pa vaccines in development, none have been licensed. The goal of our technology is a prophylactic vaccine that prevents initial colonization by Pa, regardless of serotype, to protect vulnerable patients, which we are targeting as mature adults for this study, prior to biofilm formation and host adaptation. When Phase I is completed, we will have optimized the vaccine formulation and demonstrated protective efficacy in mice and rabbit models.

总结